Absence of Interaction Between Atorvastatin or Other Statins and Clopidogrel

Open Access
Publisher Website
Google Scholar
Abstract
Clopidogrel, a thienopyridine, is a platelet adenosine diphosphate (ADP) receptor blocker found useful during and after coronary stenting.1-4 Several large randomized clinical trials and their meta-analyses5 have demonstrated benefits of clopidogrel as an alternative2 or an adjunct3,4 to aspirin in patients at high risk for cardiovascular events. Likewise, in randomized trials of secondary and primary prevention of cardiovascular disease and their meta-analyses,6 statins were found to reduce risks of myocardial infarction, stroke, and cardiovascular death. Furthermore, in a recent randomized trial of patients undergoing percutaneous coronary intervention, statins were found to reduce the incidence of major adverse coronary events, especially among patients with diabetes and those with multivessel disease.7 In these populations at especially high risk, low-density lipoprotein cholesterol (LDL) levels should be less than 100 mg/dL (2.6 mmol/L).8,9